Claims for Patent: 8,298,568

Summary for Patent: 8,298,568

Title:	Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
Abstract:	A well tolerated oil-in-water emulsion useful as a delivery vehicle of hydrophobic ingredients such as pharmaceutical drugs, wherein the emulsion particles have a net positive charge and comprises 0.001 to 0.1% of a cationic agent, 0 to 1% of a non ionic surfactant and 0 to 0.5% of an anionic surfactant.
Inventor(s):	Bague; Severine (Marcoussis, FR), Philips; Betty (Antony, FR), Garrigue; Jean-Sebastien (Verrieres le Buisson, FR), Rabinovich-Guilatt; Laura (Paris, FR), Lambert; Gregory (Malabry, FR)
Assignee:	Novagali Pharma SA (Evry, FR)
Application Number:	10/991,346
Patent Claims:	1. An oil-in-water emulsion, comprising: colloid particles having an oily core surrounded by an interfacial film; said interfacial film having an overall positive charge and comprising, based on total emulsion weight: 1) 0.001 to 0.05% by weight of a cationic agent, said cationic agent being cetalkonium chloride, 2) a non ionic surfactant, said nonionic surfactant being present in an amount up to 1% by weight and consisting of tyloxapol and poloxamer, and 3) 0% by weight of phospholipids; and said oil core being not higher than 5% weight. 2. The oil-in-water emulsion according to claim 1, wherein the concentration of the oily core is about 0.5 to 3% w/w. 3. The oil-in-water emulsion according to claim 1, wherein said colloidal particles have an average particle size of about 0.1 to 1 .mu.m. 4. The oil-in-water emulsion according to claim 3, wherein said colloidal particles have an average particle size of about 300 nm. 5. The oil-in-water emulsion according to claim 3, wherein said colloidal particles have an average particle size of about 100 to 200 nm. 6. A pharmaceutical composition comprising a pharmaceutically effective amount of a well tolerated carrier with an active ingredient, said carrier being an oil-in-water emulsion according to claim 1. 7. The pharmaceutical composition according to claim 6, wherein said composition is an ophthalmic preparation. 8. The pharmaceutical composition according to claim 6, wherein the active ingredient is sirolimus.